Group One Trading
LYEL icon

Group One Trading’s Lyell Immunopharma LYEL Stock Holding History

Group One Trading’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$20.1K – 8100
2026
Q1 		$20.1K Sell
1,000
-100
-9% -$2.34K ﹤0.01% 5963
2025
Q4 		$33.9K Sell
1,100
-1,600
-59% -$35.8K ﹤0.01% 5918
2025
Q3 		$43.8K Buy
+2,700
New +$30.8K ﹤0.01% 6073
2025
Q1 		– Sell
-150
Closed -$1.92K – 8044
2024
Q4 		$1.92K Hold
150
– – ﹤0.01% 6752
2024
Q3 		$4.14K Sell
150
-295
-66% -$8.67K ﹤0.01% 5948
2024
Q2 		$12.9K Buy
445
+435
+4,350% +$20.7K ﹤0.01% 5503
2024
Q1 		$446 Buy
+10
New +$428 ﹤0.01% 6754
2022
Q4 		– Sell
-10
Closed -$15K – 7736
2022
Q3 		$15K Buy
10
+5
+100% +$677 ﹤0.01% 6258
2022
Q2 		$1K Buy
+5
New +$511 ﹤0.01% 7574

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Group One Trading's LYEL Position: Q2 2026 in Review

Group One Trading reduced its Lyell Immunopharma (LYEL) stake by 12% in Q2 2026, selling an estimated $217 and leaving 88 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #7138.

Group One Trading first reported a position in LYEL in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.23K in Q1 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Group One Trading held 88 shares of Lyell Immunopharma worth $1.24K as of Q2 2026.
  • Group One Trading sold 12 Lyell Immunopharma shares in Q2 2026, an estimated $217.
  • Lyell Immunopharma made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7138 holding.
  • Group One Trading first reported a position in Lyell Immunopharma in Q2 2024 and has held it in 6 quarters since.
  • Group One Trading's Lyell Immunopharma position peaked at $3.23K in Q1 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.